Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
StockNews.AI · 3 hours
AI Summary
Celldex reports positive Phase 1 healthy participant data for CDX-622, a bispecific antibody targeting soluble SCF and TSLP. Results show rapid, durable, dose-dependent reductions in serum tryptase, indicating mast cell depletion, and good tolerability across dose levels. The approach may enable broader mast cell inhibition with fewer KIT off-target effects, supporting asthma-related proof-of-concept studies.
Sentiment Rationale
Phase 1 data showing rapid, dose-dependent mast cell depletion with tolerability can unlock upside expectations for Celldex’s mast cell-focused platform and support near-term re-rating, especially if Santa-proof concept reads translate to asthma indications. Historically, early positive data on targeted mast cell therapies can trigger outsized moves when combined with a differentiated mechanism and a clear path to proof-of-concept in respiratory indications.
Trading Thesis
Near-term CLDX upside on positive Phase 1 data; potential asthma proof-of-concept milestones within 12 months.
Market-Moving
- EAACI presentation of CDX-622 data could trigger intraday CLDX volatility.
- Mast cell targeting with dual SCF/TSLP mechanism differentiates Celldex's pipeline.
- Asthma-focused Phase 1b readouts could act as near-term catalysts.
Key Facts
- CDX-622 is a bispecific antibody targeting soluble SCF and TSLP. Data show rapid, dose-dependent tryptase reductions.
- Mast cell depletion observed with durability across doses; well-tolerated at all dose levels.
- First demonstration that soluble SCF neutralization selectively inhibits KIT signaling in mast cells. PK shows extended half-life and SC bioavailability.
- Phase 1 data presented at EAACI; CDX-622 is in a Phase 1b proof-of-mechanism study for mild–moderate asthma.
Companies Mentioned
- Celldex Therapeutics (CLDX): Primary data release for CDX-622; near-term stock catalyst potential.
- CDX-622 (Celldex program) (CDX-622): Bispecific antibody targeting soluble SCF and TSLP; Phase 1 data presented.
- CDX-0159 Barzolvolimab (CDX-0159): Complementary mast cell program; potential pipeline synergy with CDX-622.
Research Analysis
Category: Research Analysis. The article reports clinical data and a program update, fitting a science-driven catalyst narrative for a specialty pharma name with near-term potential.